[The results of using high-dose methotrexate in treating osteogenic sarcoma]
- PMID: 2378085
[The results of using high-dose methotrexate in treating osteogenic sarcoma]
Abstract
The interim results of the use of high-dose methotrexate with leucovorin rescue for the treatment of 26 patients with osteogenic sarcoma are discussed. Preoperative chemotherapy was followed by marked regression of primary tumor in one out of seven patients with localized disease. In that group, metastasis-free period lasted 2, 3, 10+, 12, 17+ and 24+ months. Response was observed in two out of 19 (10.6%) cases of metastases. Toxic side-effects were moderate and were mainly nausea (38.5% of patients), vomiting (26.9%), elevation of serum transaminase levels (38.5%) and fever (30.7% of cases).
Similar articles
-
Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.Cancer Treat Rep. 1982 Sep;66(9):1687-97. Cancer Treat Rep. 1982. PMID: 6981454 No abstract available.
-
[Neo-adjuvant therapy in childhood osteogenic sarcoma: a pilot study of selective postoperative chemotherapy based on response to preoperative high-dose methotrexate].Gan To Kagaku Ryoho. 1986 May;13(5):1837-45. Gan To Kagaku Ryoho. 1986. PMID: 3486634 Japanese.
-
Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.Ann Neurol. 1978 May;3(5):441-4. doi: 10.1002/ana.410030515. Ann Neurol. 1978. PMID: 310278
-
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.Clin Adv Hematol Oncol. 2005 Apr;3(4):297-9; discussion 300-2. Clin Adv Hematol Oncol. 2005. PMID: 16167002 Review. No abstract available.
-
Methotrexate revisited.Med Pediatr Oncol. 1976;2(3):227-41. doi: 10.1002/mpo.2950020303. Med Pediatr Oncol. 1976. PMID: 790144 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical